期刊文献+

CEF新辅助化疗对乳腺癌MAPK/PI3K通路的影响

Effect of CEF neo-adjuvant for MAPK/PI3K signal pathway in breast cancer
下载PDF
导出
摘要 目的通过检测CEF方案新辅助化疗前后乳腺癌组织中pMEK和pAKT蛋白水平的改变,分析该方案疗效与MAPK和PI3K信号通路之间的关系。方法选取Ⅱ~Ⅲ期乳腺癌患者54例,行CEF方案新辅助化疗。检测患者化疗前和手术后肿瘤标本中pMEK和pAKT蛋白的表达情况,分析该化疗方案对患者pMEK、pAKT的影响和化疗效果之间的关系。结果化疗后达到PR 42例,SD 7例,PD 5例,有效率77.78%(42/54)。pMEK及pAKT的表达与化疗效果均呈负相关(P<0.05)。化疗后pMEK及pAKT的表达水平下降(P<0.05)。结论CEF方案化疗可通过抑制MAPK和PI3K通路的关键蛋白pMEK和pAKT的表达发挥治疗作用,但对pMEK和pAKT高表达的患者疗效欠佳。检测这两条通路的关键蛋白pMEK和pAKT可能对指导乳腺癌化疗和判定疗效有一定价值。 Objective To investigate the change of CEF neo-adjuvant chemotherapy (NAC) for pMEK and pAKT change in breast cancer, the mechanism of CEF neo-adjuvant chemotherapy, and analyze the effect and the relationship between the schemes MAPK and PI3K signal pathway. Methods Total of 54 patients with breast cancer in stage Ⅱ-Ⅲ were selected. These patients were randomly treated with CEF neo-adjuvant chemotherapy. The expressions of pMEK and pAKT of tumor tissues were detected by immunohistochemistry (IHC) before and after the neo-adjuvant chemotherapy. Sta- tistical methods were utilized to analyze the relationship between the therapeutic effect of CEF neo-ad- juvant chemotherapy and the expressions of pMEK and pAKT, and the influences of CEF neo-adju- vant chemotherapy to the molecules. Results 42 patients of the group got PR, 7 patients got stable of disease (SD), and 5 patients of the group got progressive of disease (PD), and effective rate was 77.78% (42/54). The expression of pMEK and pAKT were negative relationship with the therapeutic effect of CEF neo-adjuvant chemotherapy (P〈0.05). The changes of the expression of pMEK and pAKT after treated with CEF NAC were decreased and there were differences in statistical significance (P〈0.05). Conclusion CEF regimen has effect by inhibit the key protein which the expression of pMEK and pAKT of MAPK/PI3K pathway in the proliferation of breast cancer cells, but the therapy effect are poor to the patients expression of high level of pMEK and pAKT. There are certain valueby key protein of pMEK and pAKT pathway are detected and guide the chemical therapy and judge curative effect .
出处 《贵州医药》 CAS 2012年第8期683-685,共3页 Guizhou Medical Journal
基金 贵州省科学技术基金资助项目[黔科合SY(2008)3043号]
  • 相关文献

参考文献3

二级参考文献99

  • 1廖永德,龙庆红,周晟,赵金平,黄畦,付向宁.蛋白激酶B在肺鳞癌和腺癌中的表达及其临床病理意义[J].中华肿瘤杂志,2005,27(3):156-159. 被引量:9
  • 2周晓东,于皆平,于红刚,罗和生,吕农华,朱萱.蛋白激酶B在胃癌中的表达及其生物学意义[J].中华消化杂志,2005,25(7):401-405. 被引量:21
  • 3Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-3310.
  • 4Lee JC, Kumar S, Griswold DE, Underwood DC, Votta B J, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000; 47:185-201.
  • 5Hirosumi J, Tuncman'G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333-336.
  • 6Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74:49-139.
  • 7Raman M, Chen W, Cobb MH. Differential regulation of MAPKs. Oncogene 2007; 26:3100-3112.
  • 8Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001 ; 81:807-869.
  • 9Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298:1911-1912.
  • 10Yoon S, Seger R. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24:21-44.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部